Sims, John R.

Donanemab in Early Symptomatic Alzheimer Disease: The TRAILBLAZER-ALZ 2 Randomized Clinical Trial

Sims, J. R., Zimmer, J. A., Evans, C. D., Lu, M., Ardayfio, P., Sparks, J., Wessels, A. M., Shcherbinin, S., Wang, H., Monkul Nery, E. S., et al. (2023) · JAMA

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 2,932

Donanemab in Early Alzheimer’s Disease

Mintun, M. A., Lo, A. C., Duggan Evans, C., Wessels, A. M., Ardayfio, P. A., Andersen, S. W., Shcherbinin, S., Sparks, J., Sims, J. R., Brys, M., et al. (2021) · New England Journal of Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 1,728

Diagnostic value of plasma phosphorylated tau181 in Alzheimer's disease and frontotemporal lobar degeneration

Advancing Research and Treatment for Frontotemporal Lobar Degeneration (ARTFL) investigators, Thijssen, E. H., La Joie, R., Wolf, A., Strom, A., Wang, P., Iaccarino, L., Bourakova, V., Cobigo, Y., Heuer, H., et al. (2020) · Nature Medicine

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 761

Cerebrospinal fluid p-tau217 performs better than p-tau181 as a biomarker of Alzheimer's disease

Janelidze, S., Stomrud, E., Smith, R., Palmqvist, S., Mattsson, N., Airey, D. C., Proctor, N. K., Chai, X., Shcherbinin, S., Sims, J. R., et al. (2020) · Nature Communications

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 450

Trial of solanezumab in preclinical Alzheimer's disease

Sperling, R. A., Donohue, M. C., Raman, R., Rafii, M. S., Johnson, K., Masters, C. L., van Dyck, C. H., Iwatsubo, T., Marshall, G. A., Yaari, R., et al. (2023) · New England Journal of Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 429

A trial of gantenerumab or solanezumab in dominantly inherited Alzheimer’s disease

Salloway, S., Farlow, M., McDade, E., Clifford, D. B., Wang, G., Llibre-Guerra, J. J., Hitchcock, J. M., Mills, S. L., Santacruz, A. M., Aschenbrenner, A. J., et al. (2021) · Nature Medicine

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 359

Association of Donanemab Treatment With Exploratory Plasma Biomarkers in Early Symptomatic Alzheimer Disease: A Secondary Analysis of the TRAILBLAZER-ALZ Randomized Clinical Trial

Pontecorvo, M. J., Lu, M., Burnham, S. C., Schade, A. E., Dage, J. L., Shcherbinin, S., Collins, E. C., Sims, J. R., & Mintun, M. A. (2022) · JAMA Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 261

Association of Amyloid Reduction After Donanemab Treatment With Tau Pathology and Clinical Outcomes: The TRAILBLAZER-ALZ Randomized Clinical Trial

Shcherbinin, S., Evans, C. D., Lu, M., Andersen, S. W., Pontecorvo, M. J., Willis, B. A., Gueorguieva, I., Hauck, P. M., Brooks, D. A., Mintun, M. A., et al. (2022) · JAMA Neurology

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 210

Dopamine Receptor Activation Modulates GABA Neuron Migration from the Basal Forebrain to the Cerebral Cortex

Crandall, J. E., McCarthy, D. M., Araki, K. Y., Sims, J. R., Ren, J.-Q., & Bhide, P. G. (2007) · The Journal of Neuroscience

Neurogenesis and neuroplasticity mechanismsNeurotransmitter Receptor Influence on Behavior

Cited by 134

Cognitive outcomes in trials of two BACE inhibitors in Alzheimer's disease

Wessels, A. M., Lines, C., Stern, R. A., Kost, J., Voss, T., Mozley, L. H., Furtek, C., Mukai, Y., Aisen, P. S., Cummings, J. L., et al. (2020) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 86

A COMBINED MEASURE OF COGNITION AND FUNCTION FOR CLINICAL TRIALS: THE INTEGRATED ALZHEIMER’S DISEASE RATING SCALE (IADRS)

Wessels, A. M., Siemers, E. R., Yu, P., Andersen, S. W., Holdridge, K. C., Sims, J. R., Sundell, K., Stern, Y., Rentz, D. M., Dubois, B., et al. (2015) · The Journal of Prevention of Alzheimer's Disease

Dementia and Cognitive Impairment ResearchAlzheimer's disease research and treatments

Cited by 86

TRAILBLAZER‐ALZ 4: A phase 3 trial comparing donanemab with aducanumab on amyloid plaque clearance in early, symptomatic Alzheimer's disease

Salloway, S., Pain, A., Lee, E., Papka, M., Ferguson, M. B., Wang, H., Hu, H., Lu, M., Oru, E., Ardayfio, P. A., et al. (2025) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 37

Use of Donanemab in Early Symptomatic Alzheimer Disease—Reply

Evans, C. D., & Sims, J. R. (2023) · JAMA

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 35

Lanabecestat: Neuroimaging results in early symptomatic Alzheimer’s disease

Zimmer, J. A., Shcherbinin, S., Devous, M. D., Bragg, S. M., Selzler, K. J., Wessels, A. M., Shering, C., Mullen, J., Landry, J., Andersen, S. W., et al. (2021) · Alzheimer's & Dementia: Translational Research & Clinical Interventions

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 27

Targeting amyloid β in Alzheimer’s disease: Meta-analysis of low-dose solanezumab in Alzheimer’s disease with mild dementia studies

Holdridge, K. C., Yaari, R., Hoban, D. B., Andersen, S., & Sims, J. R. (2023) · Alzheimer's & Dementia

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 19

1978 Donanemab in early symptomatic Alzheimer’s Disease: Efficacy and safety in TRAILBLAZER-ALZ 2, Phase 3 Randomized Clinical Trial

Mintun, M., Ritchie, C., Solomon, P., Sims, J. R., Salloway, S., Hansson, O., Apostolova, L. G., Zimmer, J. A., Evans, C. D., Lu, M., et al. (2024) · Age and Ageing

Alzheimer's disease research and treatmentsDementia and Cognitive Impairment Research

Cited by 8